Laurion Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Laurion Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,431	Closed	-$621K	–	908
2021 Q2	$621K	Sell	2,431 -3,657	-60%	-$913K	﹤0.01%	491
2021 Q1	$1.62M	Sell	6,088 -2,311	-28%	-$728K	0.01%	448
2020 Q4	$3.1M	Buy	+8,399	New	+$2.41M	0.02%	298
2019 Q2	–	Sell	-3,801	Closed	-$1.59M	–	1238
2019 Q1	$1.59M	Buy	3,801 +2,123	+127%	+$852K	0.02%	431
2018 Q4	$511K	Buy	+1,678	New	+$542K	0.01%	689

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Laurion Capital Management's EIGR Position: Q3 2021 in Review

Laurion Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2021, closing a stake of 2,431 shares — an estimated $621K sold.

Laurion Capital Management first reported a position in EIGR in Q4 2018 and held it in 5 quarters. The position peaked at $3.1M in Q4 2020. 92 funds tracked by Wall St. Rank hold EIGR as of Q3 2021.

Laurion Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Laurion Capital Management sold 2,431 Eiger BioPharmaceuticals, Inc. shares in Q3 2021, an estimated $621K.
Laurion Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 5 quarters.
Laurion Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $3.1M in Q4 2020.
92 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2021.

Based on Laurion Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.